Abstract
Septic shock is the prototype of distributive shock characterized by arteriolar and venous vasodilation and pronounced vascular leakage, resulting in tissue edema, low systemic vascular resistance (SVR) and a subsequent fall in mean arterial pressure (MAP) [1]. Multiple mechanisms are involved in the pathogenesis of the vasodilatation noticed in septic shock. Excessive nitric oxide (NO) formation subsequent to upregulation of inducible NO synthase (iNOS) and increased activity of the neuronal NOS isoform (nNOS) represents a major contributor to vasodilation, basically mediated by interaction with the cyclic guanosine monophosphate (cGMP) pathway [1]. In addition, there is increasing evidence that adenosine triphosphate (ATP)-sensitive potassium (K+ ATP) channels are critically involved in the regulation of arterial vascular smooth muscle tone, as well as in the pathophysiology of catecholamine tachyphylaxis in the presence of systemic inflammation and shock states [1, 2]. Further mechanisms include adrenoceptor desensitization and downregulation due to high circulating levels of catecholamines [3, 4]. Last but not least, vasopressin deficiency has been considered as a causative factor in the pathogenesis of vasodilation in septic shock [1, 5].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Landry DW, Oliver JA (2001) The pathogenesis of vasodilatory shock. N Engl J Med 345: 588–595
Lange M, Morelli A, Ertmer C, et al (2007) Role of adenosine triphosphate-sensitive potassium channel inhibition in shock states: Physiology and clinical implications. Shock 28:394–400
Saito T, Takanashi M, Gallagher E, et al (1995) Corticosteroid effect on early beta-adrenergic down-regulation during circulatory shock: hemodynamic study and beta-adrenergic receptor assay. Intensive Care Med 21:204–210
Hotchkiss RS, Karl IE (2003) The pathophysiology and treatment of sepsis. N Engl J Med 348:138–150
Landry DW, Levin HR, Gallant EM, et al (1997) Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 95:1122–1125
Hollenberg SM, Ahrens TS, Annane D, et al (2004) Practice parameters for hemodynamic support of sepsis in adult patients: 2004 update. Crit Care Med 32:1928–1948
Dellinger RP, Carlet JM, Masur H, et al (2004) Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 32:858–873
Holmes CL, Patel BM, Russell JA, Walley KR (2001) Physiology of vasopressin relevant to management of septic shock. Chest 120:989–1002
Westphal M, van Aken H, Ertmer C (2004) Role of vasopressin and terlipressin in the setting of systemic inflammation. In: Vincent JL (ed) Yearbook of Intensive Care and Emergency Medicine. Springer, Hedielber 9, pp 193–205
Holmes CL, Walley KR (2004) Vasopressin in the ICU. Curr Opin Crit Care 10:442–448
Cartotto R, McGibney K, Smith T, Abadir A (2007) Vasopressin for the septic burn patient. Burns 33:441–451
Barrett LK, Singer M, Clapp LH (2007) Vasopressin: mechanisms of action on the vasculature in health and in septic shock. Crit Care Med 35:33–40
Lee CS (2006) Role of exogenous arginine vasopressin in the management of catecholaminerefractory septic shock. Crit Care Nurse 26:17–23
Ertmer C, Bone HG, Westphal M (2006) Arginine vasopressin versus norepinephrine: will the stronger one win the race? Crit Care 10:144
Vincent JL (2006) Vasopressin in hypotensive and shock states. Crit Care Clin 22:187–197
Nilsson G, Lindblom P, Ohlin M, Berling R, Vernersson E (1990) Pharmacokinetics of terlipressin after single i.v. doses to healthy volunteers. Drugs Exp Clin Res 16:307–314
Pesaturo AB, Jennings HR, Voils SA (2006) Terlipressin: vasopressin analog and novel drug for septic shock. Ann Pharmacother 40:2170–2177
Forsling ML, Aziz LA, Miller M, Davies R, Donovan B (1980) Conversion of triglycylvasopressin to lysine-vasopressin in man. J Endocrinol 85:237–244
O’Brien A, Clapp L, Singer M (2002) Terlipressin for norepinephrine-resistant septic shock. Lancet 359:1209–1210
Morelli A, Rocco M, Conti G, et al (2004) Effects of terlipressin on systemic and regional haemodynamics in catecholamine-treated hyperkinetic septic shock. Intensive Care Med 30:597–604
Albanese J, Leone M, Delmas A, Martin C (2005) Terlipressin or norepinephrine in hyperdynamic septic shock: a prospective, randomized study. Crit Care Med 33:1897–1902
Leone M, Albanese J, Delmas A, Chaabane W, Gamier F, Martin C (2004) Terlipressin in catecholamine-resistant septic shock patients. Shock 22:314–319
Morelli A, Ertmer C, Lange M, Westphal M (2007) Continuous terlipressin infusion in patients with septic shock: less may be best, and the earlier the better? Intensive Care Med 33:1699–1670
Aronsen KF, Bjorkman I, Lindstrom K, Nylander G, Mulder J (1979) The mechanism of lysine-vasopressin hemostasis in bleeding esophageal varices. Acta Chir Scand 145:231–234
Ortega R, Gines P, Uriz J, et al (2002) Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 36:941–948
Ioannou GN, Doust J, Rockey DC (2003) Systematic review: terlipressin in acute oesophageal variceal haemorrhage. Aliment Pharmacol Ther 17:53–64
Boccara G, Ouattara A, Godet G, et al (2003) Terlipressin versus norepinephrine to correct refractory arterial hypotension after general anesthesia in patients chronically treated with renin-angiotensin system inhibitors. Anesthesiology 98:1338–1344
Scharte M, Meyer J, Van Aken H, Bone HG (2001) Hemodynamic effects of terlipressin (a synthetic analog of vasopressin) in healthy and endotoxemic sheep. Crit Care Med 29: 1756–1760
Westphal M, Stubbe H, Sielenkamper AW, et al (2003) Terlipressin dose response in healthy and endotoxemic sheep: impact on cardiopulmonary performance and global oxygen transport. Intensive Care Med 29:301–308
Asfar P, Pierrot M, Veal N, et al (2003) Low-dose terlipressin improves systemic and splanchnic hemodynamics in fluid-challenged endotoxic rats. Crit Care Med 31:215–220
Asfar P, Hauser B, Ivanyi Z, et al (2005) Low-dose terlipressin during long-term hyperdynamic porcine endotoxemia: effects on hepatosplanchnic perfusion, oxygen exchange, and metabolism. Crit Care Med 33:373–380
Zhao L, Brinton RD (2004) Suppression of proinflammatory cytokines interleukin-lbeta and tumor necrosis factor-alpha in astrocytes by a V1 vasopressin receptor agonist: a cAMP response element-binding protein-dependent mechanism. J Neurosci 24:2226–2235
Naylor AM, Cooper KE, Veale WL (1987) Vasopressin and fever: evidence supporting the existence of an endogenous antipyretic system in the brain. Can J Physiol Pharmacol 65:1333–1338
Lange M, Koehler G, Morelli A, et al (2007) Continuous versus bolus infusion of terlipressin in ovine endotoxemia. Shock 2007 28:623–629
Rehberg S, Ertmer C, Lange M, Morelli A, Van Aken H, Westphal M (2007) Effects of vasopressin and terlipressin in ovine septic shock on mesenteric blood flow and survival. Crit Care 11:P19 (abst)
Traber D (2007) Selective V1a receptor agonists in experimental septic shock. Crit Care 11:P51 (abst)
Landry DW, Levin HR, Gallant EM, et al (1997) Vasopressin pressor hypersensitivity in vasodilatory septic shock. Crit Care Med 25:1279–1282
Rodriguez-Nunez A, Fernandez-Sanmartin M, Martinon-Torres F, Gonzalez-Alonso N, Martinon-Sanchez JM (2004) Terlipressin for catecholamine-resistant septic shock in children. Intensive Care Med 30:477–480
Rodriguez-Nunez A, Lopez-Herce J, Gil-Anton J, Hernandez A, Rey C (2006) Rescue treatment with terlipressin in children with refractory septic shock: a clinical study. Crit Care 10:R20
Zeballos G, Lopez-Herce J, Fernandez C, Brandstrup KB, Rodriguez-Nunez A (2006) Rescue therapy with terlipressin by continuous infusion in a child with catecholamine-resistant septic shock. Resuscitation 68:151–153
Westphal M, Ertmer C, Van Aken H, Bone HG (2004) Terlipressin in patients with septic shock: friend or foe? Intensive Care Med 30:992
Morelli A, Ertmer C, Lange M, Broking K, Orecchioni A, Rocco M, Van Aken H, Pietropaoli P, Westphal M (2007) Effects of simultaneously infused terlipressin and dobutamine in septic shock. Crit Care A794
Dunser MW, Mayr AJ, Tur A, et al (2003) Ischemic skin lesions as a complication of continuous vasopressin infusion in catecholamine-resistant vasodilatory shock: incidence and risk factors. Crit Care Med 31:1394–1398
Jolley DH, De Keulenaer BL, Potter A, Stephens DP (2003) Terlipressin infusion in catecholamine-resistant shock. Anaesth Intensive Care 31:560–564
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer Science + Business Media Inc.
About this paper
Cite this paper
Ertmer, C., Morelli, A., Westphal, M. (2008). Terlipressin in Septic Shock: When and How Much?. In: Vincent, JL. (eds) Intensive Care Medicine. Springer, New York, NY. https://doi.org/10.1007/978-0-387-77383-4_40
Download citation
DOI: https://doi.org/10.1007/978-0-387-77383-4_40
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-77382-7
Online ISBN: 978-0-387-77383-4
eBook Packages: MedicineMedicine (R0)